ID21358A - Konjugat yang berguna dalam pengobatan kanker prostat - Google Patents

Konjugat yang berguna dalam pengobatan kanker prostat

Info

Publication number
ID21358A
ID21358A IDW990259A ID990259A ID21358A ID 21358 A ID21358 A ID 21358A ID W990259 A IDW990259 A ID W990259A ID 990259 A ID990259 A ID 990259A ID 21358 A ID21358 A ID 21358A
Authority
ID
Indonesia
Prior art keywords
treatment
prostate cancer
consequent use
consequent
prostate
Prior art date
Application number
IDW990259A
Other languages
English (en)
Indonesian (id)
Inventor
Victor M Garsky
Dong-Mei Feng
Deborah Defeo-Jones
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9626309.0A external-priority patent/GB9626309D0/en
Priority claimed from GBGB9718160.6A external-priority patent/GB9718160D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of ID21358A publication Critical patent/ID21358A/id

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
IDW990259A 1996-10-30 1997-10-27 Konjugat yang berguna dalam pengobatan kanker prostat ID21358A (id)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2922496P 1996-10-30 1996-10-30
GBGB9626309.0A GB9626309D0 (en) 1996-12-18 1996-12-18 Conjugates useful in the treatment of prostate cancer
US4292197P 1997-04-04 1997-04-04
GBGB9718160.6A GB9718160D0 (en) 1997-08-28 1997-08-28 Conjugates useful in the treatment of prostate cancer

Publications (1)

Publication Number Publication Date
ID21358A true ID21358A (id) 1999-05-27

Family

ID=27451580

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW990259A ID21358A (id) 1996-10-30 1997-10-27 Konjugat yang berguna dalam pengobatan kanker prostat

Country Status (31)

Country Link
EP (1) EP0942754B1 (de)
JP (1) JP2000509407A (de)
KR (1) KR100508199B1 (de)
AR (1) AR008907A1 (de)
AT (1) ATE239509T1 (de)
AU (1) AU726434B2 (de)
BG (1) BG64768B1 (de)
BR (1) BR9712589A (de)
CA (1) CA2268738A1 (de)
CO (1) CO4930281A1 (de)
CZ (1) CZ155599A3 (de)
DE (1) DE69721810T2 (de)
DK (1) DK0942754T3 (de)
DZ (1) DZ2333A1 (de)
EA (1) EA002066B1 (de)
EE (1) EE03858B1 (de)
ES (1) ES2196374T3 (de)
HR (1) HRP970566A2 (de)
HU (1) HUP0000651A3 (de)
ID (1) ID21358A (de)
IL (1) IL129356A0 (de)
IS (1) IS5025A (de)
NO (1) NO992069L (de)
PE (1) PE17399A1 (de)
PL (1) PL333004A1 (de)
PT (1) PT942754E (de)
SK (1) SK57399A3 (de)
TR (1) TR199901485T2 (de)
TW (1) TW425286B (de)
WO (1) WO1998018493A2 (de)
YU (1) YU21399A (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200002260T2 (tr) * 1997-12-02 2000-12-21 Merck & Co., Inc. Prostat kanserinin tedavisinde yararlı konjugatlar
CA2238257A1 (en) * 1998-05-22 1999-11-22 Universite De Montreal Endocytosis of amf-r and uses thereof in cancer therapy
AU764603B2 (en) * 1998-07-17 2003-08-21 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Water-soluble drugs and methods for their production
US6174858B1 (en) 1998-11-17 2001-01-16 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
PT1144011E (pt) * 1998-12-11 2010-06-16 Coulter Pharm Inc Compostos pró-fármacos e processo para a sua preparação
GB9924759D0 (en) 1999-10-19 1999-12-22 Merck Sharp & Dohme Process for preparing peptide intermediates
EP1225918A2 (de) * 1999-10-19 2002-07-31 Merck & Co., Inc. Konjugaten verwendbar bei prostata-krebs
CA2387901A1 (en) * 1999-10-27 2001-05-03 Merck & Co., Inc. Salt form of a conjugate useful in the treatment of prostate cancer
EE200200522A (et) 2000-03-15 2004-04-15 Bristol-Myers Squibb Pharma Company Toimeainega konjugeerunud ensüüm-lõhustuv peptiid, seda sisaldav farmatseutiline kompositsioon ningühendi kasutamine kasvajavastase ravimina
IL163666A0 (en) * 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
US20050187147A1 (en) * 2003-09-22 2005-08-25 Newman Michael J. Compositions and methods for increasing drug efficiency
CN100372862C (zh) * 2003-11-05 2008-03-05 天津和美生物技术有限公司 具有抗癌活性的阿霉素衍生物及其制备方法和应用
US8518891B2 (en) * 2006-11-29 2013-08-27 Longqin Hu Chemotherapeutic conjugates and methods of use
CN101225094A (zh) * 2007-01-18 2008-07-23 天津和美生物技术有限公司 具有抗癌活性的蒽醌四环类化合物
WO2010102788A1 (en) * 2009-03-09 2010-09-16 Ktb Tumorforschungsgesellschaft Mbh Prodrugs
US9402916B2 (en) 2011-03-17 2016-08-02 The University Of Birmingham Re-directed immunotherapy
RU2666530C2 (ru) 2012-01-12 2018-09-11 Йейл Юниверсити Соединения и способы усиления деградации белков-мишеней и других полипептидов с помощью е3 убиквитин лигазы
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
EP3253419A1 (de) 2015-02-02 2017-12-13 The University of Birmingham Zieleinheit-peptidepitopkomplexe mit einer vielzahl von t-zell-epitopen
PT3377103T (pt) 2015-11-19 2021-05-26 Revitope Ltd Complementação de fragmento de anticorpo funcional para um sistema de dois componentes para exterminação redirecionada de células indesejadas
WO2022136586A1 (en) 2020-12-22 2022-06-30 Cobiores Nv Compounds comprising a tetrapeptidic moiety
WO2022167664A1 (en) 2021-02-07 2022-08-11 Cobiores Nv Compounds comprising a tetrapeptidic moiety

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
US6143864A (en) * 1994-06-28 2000-11-07 Merck & Co., Inc. Peptides
EP0855910A4 (de) * 1995-10-18 2000-07-05 Merck & Co Inc Verwendbare konjugate zur behandlung der gutartigen prostatehyperplasie

Also Published As

Publication number Publication date
HUP0000651A2 (hu) 2000-06-28
AR008907A1 (es) 2000-02-23
HK1024876A1 (en) 2000-10-27
PL333004A1 (en) 1999-11-08
YU21399A (sh) 2000-03-21
BG64768B1 (bg) 2006-03-31
EA199900428A1 (ru) 2000-02-28
PE17399A1 (es) 1999-02-20
WO1998018493A3 (en) 1998-07-23
EP0942754B1 (de) 2003-05-07
CZ155599A3 (cs) 1999-10-13
EE03858B1 (et) 2002-10-15
DK0942754T3 (da) 2003-08-04
HRP970566A2 (en) 1998-08-31
SK57399A3 (en) 2000-01-18
JP2000509407A (ja) 2000-07-25
HUP0000651A3 (en) 2001-12-28
KR100508199B1 (ko) 2005-08-17
DZ2333A1 (fr) 2002-12-28
DE69721810D1 (de) 2003-06-12
ES2196374T3 (es) 2003-12-16
EE9900179A (et) 1999-12-15
IL129356A0 (en) 2000-02-17
TR199901485T2 (xx) 1999-08-23
NO992069D0 (no) 1999-04-29
CA2268738A1 (en) 1998-05-07
BG103436A (en) 2000-04-28
ATE239509T1 (de) 2003-05-15
EP0942754A2 (de) 1999-09-22
NO992069L (no) 1999-06-30
TW425286B (en) 2001-03-11
DE69721810T2 (de) 2004-03-11
AU726434B2 (en) 2000-11-09
EA002066B1 (ru) 2001-12-24
IS5025A (is) 1999-04-13
BR9712589A (pt) 1999-10-26
CO4930281A1 (es) 2000-06-27
PT942754E (pt) 2003-08-29
AU5149798A (en) 1998-05-22
KR20000052970A (ko) 2000-08-25
WO1998018493A2 (en) 1998-05-07

Similar Documents

Publication Publication Date Title
ID21358A (id) Konjugat yang berguna dalam pengobatan kanker prostat
EG21382A (en) Treatment of water
HUS1500001I1 (hu) ET743 alkalmazása kombinációs terápiában dexametazollal rákbetegség kezelésére
FI955709L (fi) Indolokarbatsolijohdannaisten käyttö eturauhasen patologisten tilojen hoidossa
HUP0004326A3 (en) Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
ID24735A (id) Konjugat-konjugat yang berguna pada pengobatan kanker prostat
UA66793C2 (uk) Лептин як стримувач швидкого збільшення пухлини клітини
IL147748A0 (en) Use of etodolac to treat cancer
GB9811598D0 (en) Diagnosis and treatment of cancer
PT984777E (pt) Piperazinas arilsubstituidas uteis no tratamento da hiperplasia benigna da prostata
ZA9810974B (en) Conjugates useful in the treatment of prostate cancer
IL149281A0 (en) Treatment of cancer
GB9819999D0 (en) Treatment of cancer
GB2343629B (en) Treatment of cellulite
GB9606293D0 (en) Treatment of cancers and other tumours
ID19871A (id) Turunan-turunan kuinoksalin yang berguna dalam terapi
AUPO851597A0 (en) Treatment of prostate cancer
GB9617941D0 (en) New approach to the treatment of prostate cancer
GB9624170D0 (en) Conjugates useful in the treatment of prostate cancer
GB9626309D0 (en) Conjugates useful in the treatment of prostate cancer
SI0942754T1 (en) Conjugates useful in the treatment of prostate cancer
SI1011649T1 (en) Use of endipalene in the treatment of psoriasis
GB9718160D0 (en) Conjugates useful in the treatment of prostate cancer
AU8719298A (en) Treatment of prostate cancer
ZA979655B (en) Conjugates useful in the treatment of prostate cancer.